Institutional investors purchased a net $48.7 million shares of TEVA during the quarter ended September 2017. This may signal that the smart money is gaining interest in this company as the 53.67% of shares outstanding that institutional investors hold is actually below the Pharmaceuticals: Generic industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ABRAMS CAPITAL MANAGEMENT LP Bought 21.6 Million shares of Teva Pharmaceutical
WELLINGTON MANAGEMENT CO. LLP Bought 10.9 Million shares of Teva Pharmaceutical
TEMPLETON GLOBAL ADVISORS LTD. Bought 5.1 Million shares of Teva Pharmaceutical